Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 7, 2003
Drug resistance reversal--are we getting closer?
R D Baird, S B Kaye
The Journal of Experimental Medicine
|
October 30, 2009
AMOUNT AND DURATION OF IMMUNITY INDUCED BY INTRADERMAL INOCULATION OF CULTURED VACCINE VIRUS
T M Rivers, S M Ward, R D Baird
The Journal of Experimental Medicine
|
October 30, 2009
A SOLUBLE ANTIGEN OF LYMPHOCYTIC CHORIOMENINGITIS : II. CHARACTERISTICS OF THE ANTIGEN AND ITS USE IN PRECIPITIN REACTIONS
J E Smadel, M J Wall, R D Baird
The Journal of Experimental Medicine
|
October 30, 2009
A SOLUBLE ANTIGEN OF LYMPHOCYTIC CHORIOMENINGITIS : I. SEPARATION OF SOLUBLE ANTIGEN FROM VIRUS
J E Smadel, R D Baird, M J Wall
European Journal of Gynaecological Oncology
|
May 23, 2012
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials
J Vitfell-Pedersen, T A Yap, V Moreno, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 10, 2018
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
H-T Arkenau, A Italiano, G Mak, et al.
ESMO Open
|
January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1
C Vaklavas, M Oliveira, A C Armstrong, et al.
Nature Communications
|
June 10, 2022
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
R C Coombes, P D Badman, J P Lozano-Kuehne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2024
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
E Hamilton, M Oliveira, N Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2026
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study
P Schmid, H-C Wang, F Lynce, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
European Journal of Cancer (Oxford, England : 1990)
|
November 7, 2003
Drug resistance reversal--are we getting closer?
R D Baird, S B Kaye
The Journal of Experimental Medicine
|
October 30, 2009
AMOUNT AND DURATION OF IMMUNITY INDUCED BY INTRADERMAL INOCULATION OF CULTURED VACCINE VIRUS
T M Rivers, S M Ward, R D Baird
The Journal of Experimental Medicine
|
October 30, 2009
A SOLUBLE ANTIGEN OF LYMPHOCYTIC CHORIOMENINGITIS : II. CHARACTERISTICS OF THE ANTIGEN AND ITS USE IN PRECIPITIN REACTIONS
J E Smadel, M J Wall, R D Baird
The Journal of Experimental Medicine
|
October 30, 2009
A SOLUBLE ANTIGEN OF LYMPHOCYTIC CHORIOMENINGITIS : I. SEPARATION OF SOLUBLE ANTIGEN FROM VIRUS
J E Smadel, R D Baird, M J Wall
European Journal of Gynaecological Oncology
|
May 23, 2012
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials
J Vitfell-Pedersen, T A Yap, V Moreno, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 10, 2018
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
H-T Arkenau, A Italiano, G Mak, et al.
ESMO Open
|
January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1
C Vaklavas, M Oliveira, A C Armstrong, et al.
Nature Communications
|
June 10, 2022
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
R C Coombes, P D Badman, J P Lozano-Kuehne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2024
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
E Hamilton, M Oliveira, N Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2026
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study
P Schmid, H-C Wang, F Lynce, et al.
Page
of 1